CoChat
Sign Up
Cited by 377MicroRNA in disease regulationCancer-related molecular mechanisms researchRNA regulation and disease

MicroRNA-155: A Master Regulator of Inflammation

Open access
Mahesh, Guruswamy, Biswas, Roopa·2019·Journal of Interferon & Cytokine Research
DOI 10.1089/jir.2018.0155PMC PMC6591773
Open this paper in CoChat — free accountOpen PDF

Abstract

MicroRNAs (miRNAs) are naturally occurring, highly conserved families of transcripts (∼22 nucleotides in length) that are processed from larger hairpin precursors. miRNAs primarily regulate gene expression by promoting messenger RNA (mRNA) degradation or repressing mRNA translation. miRNAs have been shown to be important regulators of a variety of cellular processes involving development, differentiation, and signaling. Moreover, various human diseases, including cancer and immune dysfunction, are associated with aberrant expression of miRNAs. This review will focus on how the multifunctional miRNA, miR-155, regulates inflammatory diseases, including cancer and pulmonary disorders, and also how miR-155 expression and biogenesis are regulated. We will also provide examples of miR-155-regulated networks in coordination with other noncoding RNAs, including long noncoding RNAs as well as coding mRNAs acting as competing endogenous RNAs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/jir.2018.0155

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. Ambros V. 2004. The functions of animal microRNAs. Nature 431(7006):350-355.
  2. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltz- man WM, Slack FJ. 2012. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109(26):E1695- E1704.
  3. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122(4):553-563.
  4. Bak M, Jazwa A, Kasper L, Kachamakova-Trojanowska N, Jozkowicz A, Sladek K, Dulak J. 2015. Involvement of mi- croRNAs in the inflammatory pathways of pulmonary sar- coidosis. J Physiol Pharmacol 66(5):635-642.
  5. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mecha- nism, and function. Cell 116(2):281-297.
  6. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136(2):215-233.
  7. Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Ar- mistead D, Jozwik C, Srivastava M, Pollard HB, Biswas R. 2011. Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem 286(13):11604-11615.
  8. Bhattacharyya S, Kumar P, Tsuchiya M, Bhattacharyya A, Biswas R. 2013. Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: antagonistic role of two mRNA- destabilizing proteins, KSRP and TTP. Biochem Biophys Res Commun 433(4):484-488.
  9. Brown CY, Dayan S, Wong SW, Kaczmarek A, Hope CM, Pederson SM, Arnet V, Goodall GJ, Russell D, Sadlon TJ, Barry SC. 2018. FOXP3 and miR-155 cooperate to control the invasive potential of human breast cancer cells by down regulating ZEB2 independently of ZEB1. Oncotarget 9(45): 27708-27727.
  10. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, Simpson DA, Leonard MO, Tambuwala MM, Cummins EP, Taylor CT. 2011. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 31(19):4087-4096.
  11. Calame K. 2007. MicroRNA-155 function in B Cells. Immunity 27(6):825-827.
  12. Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. 2016. Tumor- suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and acti- vating FBXW7 function. Am J Cancer Res 6(11):2561-2574.
  13. Chen L, Wang W, Cao L, Li Z, Wang X. 2016. Long Non- Coding RNA CCAT1 Acts as a Competing Endogenous RNA to Regulate Cell Growth and Differentiation in Acute Mye- loid Leukemia. Mol Cells 39(4):330-336.
  14. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE. 1990. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63(4):827-834.
  15. Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, Blelloch R, Schroth GP, Nusbaum C, Bartel DP. 2010. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 24(10):992-1009.
  16. Consortium EP. 2012. An integrated encyclopedia of DNA el- ements in the human genome. Nature 489(7414):57-74.
  17. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. 2006. Pre-B cell proliferation and lympho- blastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103(18):7024- 7029.
  18. Croce CM. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704-714.
  19. Czech B, Hannon GJ. 2011. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 12(1):19-31.
  20. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. 1993. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 34(2):159-161.
  21. Du T, Zamore PD. 2007. Beginning to understand microRNA function. Cell Res 17(8):661-663.
  22. Dunand-Sauthier I, Santiago-Raber ML, Capponi L, Vejnar CE, Schaad O, Irla M, Seguin-Estevez Q, Descombes P, Zdobnov EM, Acha-Orbea H, Reith W. 2011. Silencing of c-Fos ex- pression by microRNA-155 is critical for dendritic cell maturation and function. Blood 117(17):4490-4500.
  23. El Hajj P, Gilot D, Migault M, Theunis A, van Kempen LC, Sales F, Fayyad-Kazan H, Badran B, Larsimont D, Awada A, Bachelot L, Galibert MD, Ghanem G, Journe F. 2015. SNPs at miR-155 binding sites of TYRP1 explain discrepancy be- tween mRNA and protein and refine TYRP1 prognostic value in melanoma. Br J Cancer 113(1):91-98.
  24. Elton TS, Selemon H, Elton SM, Parinandi NL. 2013. Reg- ulation of the MIR155 host gene in physiological and path- ological processes. Gene 532(1):1-12.
  25. Esteller M. 2011. Non-coding RNAs in human disease. Nat Rev Genet 12(12):861-874.
  26. Etna MP, Sinigaglia A, Grassi A, Giacomini E, Romagnoli A, Pardini M, Severa M, Cruciani M, Rizzo F, Anastasiadou E, Di Camillo B, Barzon L, Fimia GM, Manganelli R, Coccia EM. 2018. Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells. PLoS Pathog 14(1):e1006790.
  27. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. 2009. miR- 155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792(6):497-505.
  28. Gilot D, Migault M, Bachelot L, Journe F, Rogiers A, Donnou- Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, Montier T, Corre S, Gautron A, Rambow F, El Hajj P, Ben Jouira R, Tartare-Deckert S, Marine JC, Felden B, Ghanem G, Galibert MD. 2017. A non-coding function of TYRP1 mRNA promotes melanoma growth. Nat Cell Biol 19(11): 1348-1357.
  29. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gom- meaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pebusque MJ, Dusetti NJ. 2007. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancre- atic tumor development. Proc Natl Acad Sci U S A 104(41): 16170-16175.
  30. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jr., Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. 2010. Transcriptome-wide identification of RNA- binding protein and microRNA target sites by PAR-CLIP. Cell 141(1):129-141.
  31. Hausser J, Syed AP, Bilen B, Zavolan M. 2013. Analysis of CDS-located miRNA target sites suggests that they can ef- fectively inhibit translation. Genome Res 23(4):604-615.
  32. Helwak A, Kudla G, Dudnakova T, Tollervey D. 2013. Map- ping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153(3):654-665.
  33. Hsin JP, Lu Y, Loeb GB, Leslie CS, Rudensky AY. 2018. The effect of cellular context on miR-155-mediated gene regu- lation in four major immune cell types. Nat Immunol 19(10): 1137-1145.
  34. Huang J, Jiao J, Xu W, Zhao H, Zhang C, Shi Y, Xiao Z. 2015. MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol Med Rep 12(5):7102-7108.
  35. Hwang HW, Mendell JT. 2006. MicroRNAs in cell prolifera- tion, cell death, and tumorigenesis. Br J Cancer 94(6):776- 780. International Human Genome Sequencing C. 2004. Finishing the euchromatic sequence of the human genome. Nature 431(7011):931-945.
  36. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. 2005. Micro- RNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070.
  37. Jakiela B, Gielicz A, Plutecka H, Hubalewska-Mazgaj M, Mastalerz L, Bochenek G, Soja J, Januszek R, Aab A, Musial J, Akdis M, Akdis CA, Sanak M. 2014. Th2-type cytokine- induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection. Am J Respir Cell Mol Biol 51(2):229-241.
  38. Jazwa A, Kasper L, Bak M, Sobczak M, Szade K, Jozkowicz A, Sladek K, Dulak J. 2015. Differential inflammatory micro- RNA and cytokine expression in pulmonary sarcoidosis. Arch Immunol Ther Exp (Warsz) 63(2):139-146.
  39. Jovanovic M, Hengartner MO. 2006. miRNAs and apoptosis: RNAs to die for. Oncogene 25(46):6176-6187.
  40. Kim VN. 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6(5):376-385.
  41. Kim VN, Han J, Siomi MC. 2009. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10(2):126-139.
  42. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. 2009. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 182(5):2578-2582.
  43. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. 2014. Upregulation of miRNA-155 promotes tumour angio- genesis by targeting VHL and is associated with poor prog- nosis and triple-negative breast cancer. Oncogene 33(6): 679-689.
  44. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. 2008. MicroRNA-155 is regulated by the trans- forming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28(22):6773-6784.
  45. Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jonson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, Wasik MA, Ralfkiaer E, Odum N, Woetmann A. 2013. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 12(12):1939-1947.
  46. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. 2005. Combinatorial microRNA target predic- tions. Nat Genet 37(5):495-500.
  47. Kurowska-Stolarska M, Hasoo MK, Welsh DJ, Stewart L, McIntyre D, Morton BE, Johnstone S, Miller AM, Asquith DL, Millar NL, Millar AB, Feghali-Bostwick CA, Hirani N, Crick PJ, Wang Y, Griffiths WJ, McInnes IB, McSharry C. 2017. The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis. J Allergy Clin Immunol 139(6):1946-1956.
  48. Lai HY, Rogers DF. 2010. Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmaco- therapy. Curr Opin Allergy Clin Immunol 10(1):67-76.
  49. Lin PY, Yu SL, Yang PC. 2010. MicroRNA in lung cancer. Br J Cancer 103(8):1144-1148.
  50. Lin XQ, Huang ZM, Chen X, Wu F, Wu W. 2018. XIST In- duced by JPX Suppresses Hepatocellular Carcinoma by Sponging miR-155-5p. Yonsei Med J 59(7):816-826.
  51. Loeb GB, Khan AA, Canner D, Hiatt JB, Shendure J, Darnell RB, Leslie CS, Rudensky AY. 2012. Transcriptome-wide miR-155 binding map reveals widespread noncanonical mi- croRNA targeting. Mol Cell 48(5):760-770.
  52. Luan T, Zhang X, Wang S, Song Y, Zhou S, Lin J, An W, Yuan W, Yang Y, Cai H, Zhang Q, Wang L. 2017. Long non- coding RNA MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p. Oncotarget 8(44):76153-76164.
  53. Malmhall C, Alawieh S, Lu Y, Sjostrand M, Bossios A, Eldh M, Radinger M. 2014. MicroRNA-155 is essential for T(H)2- mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol 133(5):1429-1438, 1438 e1- e7.
  54. Malmhall C, Johansson K, Winkler C, Alawieh S, Ekerljung L, Radinger M. 2017. Altered miR-155 Expression in Allergic Asthmatic Airways. Scand J Immunol 85(4):300-307.
  55. Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia- Flores Y, Baltimore D. 2017. An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory re- sponses. Nat Commun 8(1):851.
  56. Mashima R. 2015. Physiological roles of miR-155. Im- munology 145(3):323-333.
  57. Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L. 2015. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol 236(4):445-456.
  58. Montanini L, Smerieri A, Gulli M, Cirillo F, Pisi G, Sartori C, Amarri S, Bernasconi S, Marmiroli N, Street ME. 2016. miR- 146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CF1RDs. J Clin Endocrinol Metab 101(12):4955-4963.
  59. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. 2009. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 106(17):7113-7118.
  60. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. 2010. MicroRNA-155 promotes autoimmune inflammation by en- hancing inflammatory T cell development. Immunity 33(4): 607-619.
  61. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D. 2008. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205(3):585- 594.
  62. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104(5): 1604-1609.
  63. Okoye IS, Czieso S, Ktistaki E, Roderick K, Coomes SM, Pelly VS, Kannan Y, Perez-Lloret J, Zhao JL, Baltimore D, Lan- ghorne J, Wilson MS. 2014. Transcriptomics identified a critical role for Th2 cell-intrinsic miR-155 in mediating al- lergy and antihelminth immunity. Proc Natl Acad Sci U S A 111(30):E3081-E3090.
  64. Pennisi E. 2012. Genomics. ENCODE project writes eulogy for junk DNA. Science 337(6099):1159, 1161.
  65. Pottier N, Maurin T, Chevalier B, Puissegur MP, Lebrigand K, Robbe-Sermesant K, Bertero T, Lino Cardenas CL, Courcot E, Rios G, Fourre S, Lo-Guidice JM, Marcet B, Cardinaud B, Barbry P, Mari B. 2009. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: im- plication in epithelial-mesenchymal interactions. PLoS One 4(8):e6718.
  66. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Mac- donald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M. 2004. A pancreatic islet-specific microRNA reg- ulates insulin secretion. Nature 432(7014):226-230.
  67. Qaseem AS, Sonar S, Mahajan L, Madan T, Sorensen GL, Shamji MH, Kishore U. 2013. Linking surfactant protein SP- D and IL-13: implications in asthma and allergy. Mol Im- munol 54(1):98-107.
  68. Qayum AA, Paranjape A, Abebayehu D, Kolawole EM, Haque TT, McLeod JJ, Spence AJ, Caslin HL, Taruselli MT, Chu- manevich AP, Baker B, Oskeritzian CA, Ryan JJ. 2016. IL- 10-induced miR-155 targets SOCS1 to enhance IgE-mediated mast cell function. J Immunol 196(11):4457-4467.
  69. Quinn SR, Mangan NE, Caffrey BE, Gantier MP, Williams BR, Hertzog PJ, McCoy CE, O'Neill LA. 2014. The role of Ets2 transcription factor in the induction of microRNA-155 (miR- 155) by lipopolysaccharide and its targeting by interleukin- 10. J Biol Chem 289(7):4316-4325.
  70. Rajasagi NK, Bhela S, Varanasi SK, Rouse BT. 2017. Frontline Science: aspirin-triggered resolvin D1 controls herpes sim- plex virus-induced corneal immunopathology. J Leukoc Biol 102(5):1159-1171.
  71. Rane S, Sayed D, Abdellatif M. 2007. MicroRNA with a MacroFunction. Cell Cycle 6(15):1850-1855.
  72. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. 2011. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146(3):353-358.
  73. Segura MF, Belitskaya-Levy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E. 2010. Melanoma Mi- croRNA signature predicts post-recurrence survival. Clin Cancer Res 16(5):1577-1586.
  74. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL. 2018. Cobomarsen, an oligonucleotide in- hibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cu- taneous T-cell lymphoma. Br J Haematol 183(3):428-444.
  75. Shi Y, Fu X, Cao Q, Mao Z, Chen Y, Sun Y, Liu Z, Zhang Q. 2018. Overexpression of miR-155-5p Inhibits the Prolifera- tion and Migration of IL-13-Induced Human Bronchial Smooth Muscle Cells by Suppressing TGF-beta-Activated Kinase 1/MAP3K7-Binding Protein 2. Allergy Asthma Im- munol Res 10(3):260-267.
  76. Tam W. 2001. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 274(1-2):157-167.
  77. Tam W, Ben-Yehuda D, Hayward WS. 1997. bic, a novel gene activated by proviral insertions in avian leukosis virus- induced lymphomas, is likely to function through its non- coding RNA. Mol Cell Biol 17(3):1490-1502.
  78. Tanabe T, Fujimoto K, Yasuo M, Tsushima K, Yoshida K, Ise H, Yamaya M. 2008. Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithe- lium. Clin Exp Allergy 38(1):122-134.
  79. Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh HS, Lee SC. 2011. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia 59(12):1911- 1922.
  80. Tay Y, Rinn J, Pandolfi PP. 2014. The multilayered complexity of ceRNA crosstalk and competition. Nature 505(7483):344-352.
  81. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt- Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. 2007. Regulation of the germinal center response by microRNA-155. Science 316(5824):604-608.
  82. Tili E, Croce CM, Michaille JJ. 2009. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 28(5): 264-284.
  83. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, Croce CM. 2011. Mutator activity induced by microRNA- 155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A 108(12):4908-4913.
  84. Tsuchiya M, Kalurupalle S, Kumar P, Ghoshal S, Zhang Y, Lehrmann E, Becker KG, Gorospe M, Biswas R. 2016. RPTOR, a novel target of miR-155, elicits a fibrotic pheno- type of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol 13(9):837-847.
  85. Tsuchiya M, Kumar P, Bhattacharyya S, Chattoraj S, Srivastava M, Pollard HB, Biswas R. 2013. Differential regulation of inflammation by inflammatory mediators in cystic fibrosis lung epithelial cells. J Interferon Cytokine Res 33(3):121-129.
  86. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, Ferracin M, Lanza G, Volinia S, Negrini M, McIlhatton MA, Amadori D, Fishel R, Croce CM. 2010. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 107(15):6982-6987.
  87. van Rooij E, Olson EN. 2007. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic tar- gets. J Clin Invest 117(9):2369-2376.
  88. Zech A, Ayata CK, Pankratz F, Meyer A, Baudiss K, Cicko S, Yegutkin GG, Grundmann S, Idzko M. 2015. MicroRNA-155 modulates P2R signaling and Th2 priming of dendritic cells during allergic airway inflammation in mice. Allergy 70(9): 1121-1129.
  89. Zeng Y, Yi R, Cullen BR. 2003. MicroRNAs and small inter- fering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 100(17):9779-9784.
  90. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fer- nandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. 2012. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 120(8):1678-1686.
  91. Zheng Y, Xiong S, Jiang P, Liu R, Liu X, Qian J, Zheng X, Chu Y. 2012. Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism. Free Radic Biol Med 52(8):1307-1317.
  92. Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S, Wu L, Shen N. 2010. miR-155 and its star-form partner miR-155* co- operatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 116(26):5885-5894.

Cited by

Sorted by citations

Authors
Mahesh, G., & Biswas, R.
Affiliations
Uniformed Services University of the Health Sciences (US)
Corresponding author
Biswas, Roopa
ORCID
Venue
Journal of Interferon & Cytokine Research
Publisher
SAGE Publications
Published
2019-06
Volume
39
Issue
6
Pages
321-330
ISSN
  • 1079-9907 (ISSN-L)
  • 1557-7465
DOI
10.1089/jir.2018.0155
PMC
PMC6591773
OpenAlex
W2938480747
Cited by
377
References
5
Citations by year
2026: 34 · 2025: 54 · 2024: 77 · 2023: 72 · 2022: 63 · 2021: 54 · 2020: 15 · 2019: 7 · 2018: 1
FWCI
3.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Interferon & Cytokine Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Uniformed Services University of the Health Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords
miR-155, inflammation, microRNA biogenesis, miRNA expression regulation, inflammatory diseases, cancer, pulmonary disorders, long non-coding RNA, competing endogenous RNA, mRNA degradation, protein synthesis inhibition
MeSH terms
Humans, Inflammation, Lung Diseases, Neoplasms, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review